denix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. It develops nucleoside/nucleotide polymerase inhibitors, including IDX102 and IDX184, which are in late-stage preclinical development; protease inhibitors; and non-nucleoside polymerase inhibitors for the treatment of hepatitis C virus. The company also develops IDX899 that has completed a phase I dose-escalation study for the treatment of HIV-1 from the class of compounds known as non-nucleoside reverse transcriptase inhibitors. In addition, Idenix Pharmaceuticals holds licenses for Tyzeka and Sebivo products for the treatment of patients with chronic hepatitis B. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.
Analysts'
Recommendation: | Sell |
| 30 Days Ago: | Hold |
|
| Analysts' Target: | $19 |
| Analysts' Targets |
| Caris & Company | $19 |
| Buy |
Monday, April 21, 2008
|
$6.86 (07/13/08)
